In January I mentioned Apocell from Israeli biotech Enlivex, which prevents GVHD rejection of bone marrow transplants. Now, the treatment has received US FDA “orphan” status due to its importance and lack of alternatives for treating the unwanted autoimmune response.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000833540&fid=1725